List View

By /

Clear

Displaying 1,676 - 1,700 of 2,995

Targeted Therapy for Colon Cancer: What is New?

Targeted Therapy for Colon Cancer: What is New?

Liver and Hepatic Malignancies: Times to Overcome Challenges

Liver and Hepatic Malignancies: Times to Overcome Challenges

Developing Targeted therapy for GU malignancies

Developing Targeted therapy for GU malignancies

Targeted Therapy for Ovarian and Uterine Tumors

Targeted Therapy for Ovarian and Uterine Tumors

Head and Neck Cancers

Head and Neck Cancers

EGFR and Resistant Mechanisms

EGFR and Resistant Mechanisms

ALK, ROS-1, RET and MET

ALK, ROS-1, RET and MET

Immunotherapy in Advanced NSCLC: Initial Therapy and How to Overcome Resistance

Immunotherapy in Advanced NSCLC: Initial Therapy and How to Overcome Resistance

What Have We Learned from the Use Of Medical Marijuana: Myths and Facts

What Have We Learned from the Use Of Medical Marijuana: Myths and Facts

Most Common Adverse Events of Checkpoint Inhibitors | Current Recommendations and Management

Most Common Adverse Events of Checkpoint Inhibitors | Current Recommendations and Management

Management of Metastatic Disease Using Interventional Radiology in 2023: Y90 SirSpheres and Other Procedures

Management of Metastatic Disease Using Interventional Radiology in 2023: Y90 SirSpheres and Other Procedures

Pain Management in Cancer Patients

Pain Management in Cancer Patients

Cancer and Thrombosis: State-of-the-Art Management

Cancer and Thrombosis: State-of-the-Art Management

Novel Advances in H&N and Thyroid Cancers

Novel Advances in H&N and Thyroid Cancers

Management of Melanoma: Early and Advanced Stages

Management of Melanoma: Early and Advanced Stages

Colorectal Cancer: Chemotherapy Combinations Targeted Therapy and Immunotherapy

Colorectal Cancer: Chemotherapy Combinations Targeted Therapy and Immunotherapy

Pancreas and Biliary Carcinomas: Novel Advances

Pancreas and Biliary Carcinomas: Novel Advances

Favoring The Neoadjuvant Concept

Favoring The Neoadjuvant Concept

Favoring The Adjuvant Concept

Favoring The Adjuvant Concept

Stage IIIA-B-C NSCLC: Does The PACIFIC Data Fit All-in-One?

Stage IIIA-B-C NSCLC: Does The PACIFIC Data Fit All-in-One?

What After Immunotherapy Failure in First Line: Is There Hope?

What After Immunotherapy Failure in First Line: Is There Hope?

Management of EGFR Mutant NSCLC Patients and Future Directions (excluding Resistance to EGFR TKIs)

Management of EGFR Mutant NSCLC Patients and Future Directions (excluding Resistance to EGFR TKIs)

EGFR PKI Resistance and K-RAS Mutations

EGFR PKI Resistance and K-RAS Mutations

ALK & ROS-1: First Line & Mechanism of Resistance

ALK & ROS-1: First Line & Mechanism of Resistance

Novel Targets: HER-2, NRG1, TROP2, CEACAM5 & HER-3

Novel Targets: HER-2, NRG1, TROP2, CEACAM5 & HER-3